- Home
- GMAB vs APTV Comparison
GMAB vs APTV Comparison
Compare GMAB & APTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMAB | APTV |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Denmark | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 16.5B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | GMAB | APTV |
|---|---|---|
| Price | $27.29 | $72.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | $40.93 | ★ $96.00 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $20,398,000,000.00 |
| Revenue This Year | $17.80 | $7.33 |
| Revenue Next Year | $14.86 | $4.84 |
| P/E Ratio | ★ $1.90 | $96.76 |
| Revenue Growth | N/A | ★ 3.47 |
| 52 Week Low | $17.24 | $47.19 |
| 52 Week High | $35.43 | $88.93 |
Technical Indicators
Market Signals| Indicator | GMAB | APTV |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 38.97 |
| Support Level | $20.83 | $67.83 |
| Resistance Level | $33.75 | $87.98 |
| Average True Range (ATR) | 0.67 | 2.49 |
| MACD | -0.15 | -0.68 |
| Stochastic Oscillator | 20.06 | 24.79 |
Price Performance
Historical ComparisonAbout GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About APTV Aptiv PLC
Aptiv PLC is an industrial technology company focused on enabling a more automated, electrified and digitalized future. The company's technologies reach from sensor to cloud, including the hardware and software necessary to support automotive and other industries on a global basis. Its Advanced Safety and User Experience segment provides advanced software and services, intelligent sensors and high-performance compute platforms; its Engineered Components Group segment provides connection systems, high-performance interconnects, and cable management and protection solutions; and its Electrical Distribution Systems segment provides low voltage and high voltage power, signal and data distribution.